Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs

Human Immunology

Volumn 77, Issue 11, 2016, Pages 1092-1100

  Cross, Amy R ^a,b   Lion, Julien ^a,b   Loiseau, Pascale ^a,b   Charron, Dominique ^b,c   Taupin, Jean Luc ^a,b,c   Glotz, Denis ^a,b,c   Mooney, Nuala ^a,b  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Endothelial cell; HLA DP; HLA DQ

Indexed keywords

ALLOANTIBODY; ANTIBODY; HETERODIMER; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; PEPTIDE; EPITOPE; HLA DP ANTIGEN; HLA DQ ANTIGEN;

ALLOGRAFT; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; ENDOTHELIUM; EPIGENETICS; GENETIC REGULATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; PRIORITY JOURNAL; PROTEIN STABILITY; SIGNAL TRANSDUCTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HUMORAL IMMUNITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METABOLISM;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; EPITOPES; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNITY, HUMORAL; ISOANTIBODIES; KIDNEY TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84962888179     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.04.003     Document Type: Article

References (102)

1. [1] Lefaucheur, C., Loupy, A., Hill, G.S., Andrade, J., Nochy, D., Antoine, C., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. JASN 21:8 (2010), 1398–1406 Epub 2010/07/17.
2. [2] Lefaucheur, C., Antoine, C., Suberbielle, C., Glotz, D., Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am. J. Transplant. 11:8 (2011), 1592–1598 Epub 2011/06/15.
3. [3] Witt, C.A., Gaut, J.P., Yusen, R.D., Byers, D.E., Iuppa, J.A., Bennett Bain, K., et al. Acute antibody-mediated rejection after lung transplantation. J. Heart Lung Transplant. 32:10 (2013), 1034–1040 Epub 2013/08/21.
4. [4] Safavi, S., Robinson, D.R., Soresi, S., Carby, M., Smith, J.D., De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J. Heart Lung Transplant. 33:12 (2014), 1273–1281 Epub 2014/08/19.
5. [5] Lobo, L.J., Aris, R.M., Schmitz, J., Neuringer, I.P., Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J. Heart Lung Transplant. 32:1 (2013), 70–77 Epub 2012/12/25.
6. [6] Smith, J.D., Banner, N.R., Hamour, I.M., Ozawa, M., Goh, A., Robinson, D., et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am. J. Transplant. 11:2 (2011), 312–319 Epub 2011/01/12.
7. [7] Issa, N., Cosio, F.G., Gloor, J.M., Sethi, S., Dean, P.G., Moore, S.B., et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 86:5 (2008), 681–685 Epub 2008/09/16.
8. [8] Cosio, F.G., Gloor, J.M., Sethi, S., Stegall, M.D., Transplant glomerulopathy. Am. J. Transplant. 8:3 (2008), 492–496 Epub 2008/02/26.
9. [9] Lepin, E.J., Zhang, Q., Zhang, X., Jindra, P.T., Hong, L.S., Ayele, P., et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am. J. Transplant. 6:7 (2006), 1560–1571 Epub 2006/07/11.
10. [10] Taflin, C., Favier, B., Baudhuin, J., Savenay, A., Hemon, P., Bensussan, A., et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc. Nat. Acad. Sci. U.S.A. 108:7 (2011), 2891–2896 Epub 2011/02/02.
11. [11] Watson, C.A., Petzelbauer, P., Zhou, J., Pardi, R., Bender, J.R., Contact-dependent endothelial class II HLA gene activation induced by NK cells is mediated by IFN-gamma-dependent and -independent mechanisms. J. Immunol. 154:7 (1995), 3222–3233 Epub 1995/04/01.
12. [12] Muczynski, K.A., Ekle, D.M., Coder, D.M., Anderson, S.K., Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J. Am. Soc. Nephrol. JASN 14:5 (2003), 1336–1348 Epub 2003/04/23.
13. [13] Muczynski, K.A., Cotner, T., Anderson, S.K., Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int. 59:2 (2001), 488–497 Epub 2001/02/13.
14. [14] DeVos, J.M., Gaber, A.O., Knight, R.J., Land, G.A., Suki, W.N., Gaber, L.W., et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int. 82:5 (2012), 598–604 Epub 2012/05/25.
15. [15] Everly, M.J., Rebellato, L.M., Haisch, C.E., Ozawa, M., Parker, K., Briley, K.P., et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95:3 (2013), 410–417 Epub 2013/02/06.
16. [16] Ginevri, F., Nocera, A., Comoli, P., Innocente, A., Cioni, M., Parodi, A., et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am. J. Transplant. 12:12 (2012), 3355–3362 Epub 2012/09/11.
17. [17] Tagliamacco, A., Cioni, M., Comoli, P., Ramondetta, M., Brambilla, C., Trivelli, A., et al. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant. Transpl. Int. 27:7 (2014), 667–673 Epub 2014/03/19.
18. [18] Willicombe, M., Brookes, P., Sergeant, R., Santos-Nunez, E., Steggar, C., Galliford, J., et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 94:2 (2012), 172–177 Epub 2012/06/28.
19. [19] Wozniak, L.J., Hickey, M.J., Venick, R.S., Vargas, J.H., Farmer, D.G., Busuttil, R.W., et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation 99:7 (2015), 1416–1422 Epub 2015/06/04.
20. [20] Tambur, A.R., Haarberg, K.M., Friedewald, J.J., Leventhal, J.R., Cusick, M.F., Jaramillo, A., et al. Unintended consequences of the new national kidney allocation policy in the United States. Am. J. Transplant., 2015 Epub 2015/07/04.
21. [21] Mytilineos, J., Deufel, A., Opelz, G., Clinical relevance of HLA-DPB locus matching for cadaver kidney retransplants: a report of the collaborative transplant study. Transplantation 63:9 (1997), 1351–1354 Epub 1997/05/15.
22. [22] Laux, G., Mansmann, U., Deufel, A., Opelz, G., Mytilineos, J., A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation 75:9 (2003), 1527–1532 Epub 2003/06/07.
23. [23] Jolly, E.C., Key, T., Rasheed, H., Morgan, H., Butler, A., Pritchard, N., et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am. J. Transplant. 12:10 (2012), 2845–2848 Epub 2012/07/05.
24. [24] Cippa, P.E., Gaspert, A., Etter, C., Guenduez, Z., Ferrari-Lacraz, S., Rusi, B., et al. Late antibody-mediated rejection by de novo donor HLA-DP-specific antibody after renal transplantation: a case report. Hum. Immunol. 75:5 (2014), 462–465 Epub 2014/02/18.
25. [25] Baxter-Lowe, L.A., Cecka, M., Kamoun, M., Sinacore, J., Melcher, M.L., Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multi-center kidney exchange program. Am. J. Transplant. 14:7 (2014), 1592–1598 Epub 2014/06/18.
26. [26] Haraldsen, G., Sollid, L.M., Bakke, O., Farstad, I.N., Kvale, D., Molberg, et al. Major histocompatibility complex class II-dependent antigen presentation by human intestinal endothelial cells. Gastroenterology 114:4 (1998), 649–656 Epub 1998/04/18.
27. [27] Cunningham, A.C., Zhang, J.G., Moy, J.V., Ali, S., Kirby, J.A., A comparison of the antigen-presenting capabilities of class II MHC-expressing human lung epithelial and endothelial cells. Immunology 91:3 (1997), 458–463 Epub 1997/07/01.
28. [28] Ting, J.P., Zhu, X.S., Class II MHC genes: a model gene regulatory system with great biologic consequences. Microbes Infect. 1:11 (1999), 855–861 Institut Pasteur, Epub 1999/12/30.
29. [29] Maurer, D.H., Hanke, J.H., Mickelson, E., Rich, R.R., Pollack, M.S., Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts. J. Immunol. 139:3 (1987), 715–723 Epub 1987/08/01.
30. [30] Long, A.B., Ferguson, A.M., Majumder, P., Nagarajan, U.M., Boss, J.M., Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression. Mol. Immunol. 43:5 (2006), 395–409 Epub 2005/12/13.
31. [31] Sukiennicki, T.L., Shewey, L.M., Nepom, G.T., Locus- and allele-specific DNA-protein interactions in the HLA-DQB1 X box. Immunol. Res. 12:4 (1993), 317–329 Epub 1993/01/01.
32. [32] Hehlgans, T., Mannel, D.N., The TNF-TNF receptor system. Biol. Chem. 383:10 (2002), 1581–1585 Epub 2002/11/28.
33. [33] Stavride, P., Arampatzi, P., Papamatheakis, J., Differential regulation of MHCII genes by PRMT6, via an AT-hook motif of RFX5. Mol. Immunol. 56:4 (2013), 390–398 Epub 2013/08/06.
34. [34] Hayde, N., Broin, P.O., Bao, Y., de Boccardo, G., Lubetzky, M., Ajaimy, M., et al. Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney Int. 86:3 (2014), 600–609 Epub 2014/03/29.
35. [35] Sellares, J., Reeve, J., Loupy, A., Mengel, M., Sis, B., Skene, A., et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am. J. Transplant. 13:4 (2013), 971–983 Epub 2013/02/19.
36. [36] Otten, L.A., Steimle, V., Bontron, S., Mach, B., Quantitative control of MHC class II expression by the transactivator CIITA. Eur. J. Immunol. 28:2 (1998), 473–478 Epub 1998/04/01.
37. [37] Greer, S.F., Zika, E., Conti, B., Zhu, X.S., Ting, J.P., Enhancement of CIITA transcriptional function by ubiquitin. Nat. Immunol. 4:11 (2003), 1074–1082 Epub 2003/10/07.
38. [38] Greer, S.F., Harton, J.A., Linhoff, M.W., Janczak, C.A., Ting, J.P., Cressman, D.E., Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation. J. Immunol. 173:1 (2004), 376–383 Epub 2004/06/24.
39. [39] Wedgwood, J.F., Hatam, L., Bonagura, V.R., Effect of interferon-gamma and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical vein endothelial cells. Cell Immunol. 111:1 (1988), 1–9 Epub 1988/01/01.
40. [40] Pardi, R., Bender, J.R., Engleman, E.G., Lymphocyte subsets differentially induce class II human leukocyte antigens on allogeneic microvascular endothelial cells. J. Immunol. 139:8 (1987), 2585–2592 Epub 1987/10/15.
41. [41] Collinge, M., Pardi, R., Bender, J.R., Class II transactivator-independent endothelial cell MHC class II gene activation induced by lymphocyte adhesion. J. Immunol. 161:4 (1998), 1589–1593 Epub 1998/08/26.
42. [42] Xu, Z., Nayak, D.K., Benshoff, N., Hachem, R., Gelman, A.E., Mohanakumar, T., De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II. J. Immunol. 194:12 (2015), 6133–6143 Epub 2015/05/06.
43. [43] Beaty, J.S., Sukiennicki, T.L., Nepom, G.T., Allelic variation in transcription modulates MHC class II expression and function. Microbes Infect. 1:11 (1999), 919–927 Institut Pasteur, Epub 1999/12/30.
44. [44] Andersen, L.C., Beaty, J.S., Nettles, J.W., Seyfried, C.E., Nepom, G.T., Nepoom, B.S., Allelic polymorphism in transcriptional regulatory regions of HLA-DQB genes. J. Exp. Med. 173:1 (1991), 181–192 Epub 1991/01/01.
45. [45] Kuipers, H.F., van den Elsen, P.J., Statins and control of MHC2TA gene transcription.Nat. Med.., 11(4), 2005, 365–366 Author reply 6-7. Epub 2005/04/07.
46. [46] Lee, S.J., Qin, H., Benveniste, E.N., The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur. J. Immunol. 38:8 (2008), 2325–2336 Epub 2008/07/08.
47. [47] Schwiebert, L.M., Schleimer, R.P., Radka, S.F., Ono, S.J., Modulation of MHC class II expression in human cells by dexamethasone. Cell. Immunol. 165:1 (1995), 12–19 Epub 1995/10/01.
48. [48] Del Pozzo, G., Ciullo, M., Autiero, M., Guardiola, J., Control of nucleo-cytoplasmic HLA-DRA mRNA partitioning by interaction of a retention signal with compartmentalized proteins. J. Mol. Biol. 240:3 (1994), 193–204 Epub 1994/07/15.
49. [49] Roche, P.A., Furuta, K., The ins and outs of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15:4 (2015), 203–216 Epub 2015/02/28.
50. [50] van Lith, M., McEwen-Smith, R.M., Benham, A.M., HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM. J. Biol. Chem. 285:52 (2010), 40800–40808 Epub 2010/10/21.
51. [51] Miyadera, H., Ohashi, J., Lernmark, A., Kitamura, T., Tokunaga, K., Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. J. Clin. Invest. 125:1 (2015), 275–291 Epub 2014/12/09.
52. [52] Raychaudhuri, S., Sandor, C., Stahl, E.A., Freudenberg, J., Lee, H.S., Jia, X., et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44:3 (2012), 291–296 Epub 2012/01/31.
53. ∗02 haplotype confers susceptibility to type 1 diabetes in whites and is preferentially associated with early clinical disease onset in male subjects. Hum. Immunol. 65:7 (2004), 729–736 Epub 2004/08/11.
54. ∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:9308 (2002), 727–732 Epub 2002/03/13.
55. [55] Shiina, T., Inoko, H., Kulski, J.K., An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 64:6 (2004), 631–649 Epub 2004/11/18.
56. [56] Fallang, L.E., Bergseng, E., Hotta, K., Berg-Larsen, A., Kim, C.Y., Sollid, L.M., Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat. Immunol. 10:10 (2009), 1096–1101 Epub 2009/09/01.
57. [57] Mahlios, J., De la Herran-Arita, A.K., Mignot, E., The autoimmune basis of narcolepsy. Curr. Opin. Neurobiol. 23:5 (2013), 767–773 Epub 2013/06/04.
58. [58] Busch, R., De Riva, A., Hadjinicolaou, A.V., Jiang, W., Hou, T., Mellins, E.D., On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Expert Rev. Mol. Med., 14, 2012, e15 Epub 2012/07/19.
59. [59] Duquesnoy, R.J., Marrari, M., Mulder, A., Usefulness of the nonself-self algorithm of HLA epitope immunogenicity in the specificity analysis of monospecific antibodies induced during pregnancy. Front. Immunol., 6, 2015, 180 Epub 2015/06/16.
60. [60] Wiebe, C., Pochinco, D., Blydt-Hansen, T.D., Ho, J., Birk, P.E., Karpinski, M., et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am. J. Transplant. 13:12 (2013), 3114–3122 Epub 2013/10/30.
61. [61] Lucas, D.P., Leffell, M.S., Zachary, A.A., Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response. Transplantation 99:1 (2015), 77–85 Epub 2014/09/05.
62. [62] Kosmoliaptsis, V., Sharples, L.D., Chaudhry, A.N., Halsall, D.J., Bradley, J.A., Taylor, C.J., Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 91:2 (2011), 183–190 Epub 2010/11/17.
63. [63] Kosmoliaptsis, V., Mallon, D.H., Chen, Y., Bolton, E.M., Bradley, A.J., Taylor, C.J., Alloantibody responses after renal transplant failure can be better predicted by donor-recipient HLA amino acid sequence and physicochemical disparities than conventional HLA matching. Am. J. Transplant., 2016 Epub 2016/01/13.
64. [64] Sicard, A., Ducreux, S., Rabeyrin, M., Couzi, L., McGregor, B., Badet, L., et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J. Am. Soc. Nephrol. JASN 26:2 (2015), 457–467 Epub 2014/08/16.
65. [65] Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., Duong van Huyen, J.P., Mooney, N., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. New England J. Med. 369:13 (2013), 1215–1226 Epub 2013/09/27.
66. [66] Yell, M., Muth, B.L., Kaufman, D.B., Djamali, A., Ellis, T.M., C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 99:6 (2015), 1151–1155 Epub 2015/04/04.
67. [67] Kolev, M., Dimeloe, S., Le Friec, G., Navarini, A., Arbore, G., Povoleri, G.A., et al. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 42:6 (2015), 1033–1047 Epub 2015/06/18.
68. [68] Strainic, M.G., Liu, J., Huang, D., An, F., Lalli, P.N., Muqim, N., et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28:3 (2008), 425–435 Epub 2008/03/11.
69. [69] Raedler, H., Yang, M., Lalli, P.N., Medof, M.E., Heeger, P.S., Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am. J. Transplant. 9:8 (2009), 1784–1795 Epub 2009/07/01.
70. [70] Jane-Wit, D., Manes, T.D., Yi, T., Qin, L., Clark, P., Kirkiles-Smith, N.C., et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kappaB signaling in endothelial cells. Circulation 128:23 (2013), 2504–2516 Epub 2013/09/21.
71. [71] Hirohashi, T., Chase, C.M., Della Pelle, P., Sebastian, D., Alessandrini, A., Madsen, J.C., et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am. J. Transplant. 12:2 (2012), 313–321 Epub 2011/11/11.
72. [72] Zhang, X., Reed, E.F., Effect of antibodies on endothelium. Am. J. Transplant. 9:11 (2009), 2459–2465 Epub 2009/09/25.
73. [73] Guidicelli, G., Guerville, F., Lepreux, S., Wiebe, C., Thaunat, O., Dubois, V., Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival. J. Am. Soc. Nephrol. JASN, 2015 Epub 2015/06/07.
74. [74] Jin, Y.P., Singh, R.P., Du, Z.Y., Rajasekaran, A.K., Rozengurt, E., Reed, E.F., Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J. Immunol. 168:11 (2002), 5415–5423 Epub 2002/05/23.
75. [75] Galvani, S., Auge, N., Calise, D., Thiers, J.C., Canivet, C., Kamar, N., et al. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am. J. Transplant. 9:11 (2009), 2607–2614 Epub 2009/10/22.
76. [76] Jindra, P.T., Hsueh, A., Hong, L., Gjertson, D., Shen, X.D., Gao, F., et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J. Immunol. 180:4 (2008), 2214–2224 Epub 2008/02/06.
77. [77] Le Bas-Bernardet, S., Coupel, S., Chauveau, A., Soulillou, J.P., Charreau, B., Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation 78:12 (2004), 1729–1739 Epub 2004/12/23.
78. [78] Coupel, S., Leboeuf, F., Boulday, G., Soulillou, J.P., Charreau, B., RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J. Am. Soc. Nephrol. JASN 15:9 (2004), 2429–2439 Epub 2004/09/02.
79. [79] Taflin, C., Charron, D., Glotz, D., Mooney, N., Regulation of the CD4+ T cell allo-immune response by endothelial cells. Hum. Immunol. 73:12 (2012), 1269–1274 Epub 2012/07/21.
80. [80] Lion, J., Taflin, C., Cross, A.R., Robledo-Sarmiento, M., Mariotto, E., Savenay, A., HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion. Am. J. Transplant., 2015 Epub 2015/11/29.
81. [81] Haylett, R.S., Koch, N., Rink, L., MHC class II molecules activate NFAT and the ERK group of MAPK through distinct signaling pathways in B cells. Eur. J. Immunol. 39:7 (2009), 1947–1955 Epub 2009/06/23.
82. [82] Leveille, C., Castaigne, J.G., Charron, D., Al-Daccak, R., MHC class II isotype-specific signaling complex on human B cells. Eur. J. Immunol. 32:8 (2002), 2282–2291 Epub 2002/09/05.
83. [83] Jin, Y.P., Jindra, P.T., Gong, K.W., Lepin, E.J., Reed, E.F., Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 79:3 Suppl (2005), S19–S21 Epub 2005/02/09.
84. [84] Jindra, P.T., Jin, Y.P., Jacamo, R., Rozengurt, E., Reed, E.F., MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem. Biophys. Res. Commun. 369:2 (2008), 781–787 Epub 2008/03/04.
85. [85] Zhang, X., Rozengurt, E., Reed, E.F., HLA class I molecules partner with integrin beta4 to stimulate endothelial cell proliferation and migration. Sci. Signal., 3(149), 2010, ra85 Epub 2010/11/26.
86. [86] Khalil, H., Brunet, A., Saba, I., Terra, R., Sekaly, R.P., Thibodeau, J., The MHC class II beta chain cytoplasmic tail overcomes the invariant chain p35-encoded endoplasmic reticulum retention signal. Int. Immunol. 15:10 (2003), 1249–1263 Epub 2003/09/19.
87. [87] Zilber, M.T., Setterblad, N., Vasselon, T., Doliger, C., Charron, D., Mooney, N., et al. MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. Blood 106:9 (2005), 3074–3081 Epub 2005/06/09.
88. [88] Doisne, J.M., Castaigne, J.G., Deruyffelaere, C., Dieu-Nosjean, M.C., Chamot, C., Alcaide-Loridan, C., et al. The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes. Mol. Immunol. 45:3 (2008), 709–718 Epub 2007/08/28.
89. [89] Jin, L., Waterman, P.M., Jonscher, K.R., Short, C.M., Reisdorph, N.A., Cambier, J.C., MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol. Cell. Biol. 28:16 (2008), 5014–5026 Epub 2008/06/19.
90. [90] Draber, P., Vonkova, I., Stepanek, O., Hrdinka, M., Kucova, M., Skopcova, T., et al. SCIMP, a transmembrane adaptor protein involved in major histocompatibility complex class II signaling. Mol. Cell. Biol. 31:22 (2011), 4550–4562 Epub 2011/09/21.
91. [91] Brand, A., Doxiadis, I.N., Roelen, D.L., On the role of HLA antibodies in hematopoietic stem cell transplantation. Tissue Antigens 81:1 (2013), 1–11 Epub 2012/12/12.
92. [92] Yoshihara, S., Maruya, E., Taniguchi, K., Kaida, K., Kato, R., Inoue, T., et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 47:4 (2012), 508–515 Epub 2011/06/22.
93. [93] Ciurea, S.O., de Lima, M., Cano, P., Korbling, M., Giralt, S., Shpall, E.J., et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 88:8 (2009), 1019–1024 Epub 2009/10/27.
94. [94] Chang, Y.J., Zhao, X.Y., Xu, L.P., Zhang, X.H., Wang, Y., Han, W., et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J. Hematol. Oncol., 8, 2015, 84 Epub 2015/07/15.
95. [95] Cutler, C., Kim, H.T., Sun, L., Sese, D., Glotzbecker, B., Armand, P., et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 118:25 (2011), 6691–6697 Epub 2011/09/24.
96. [96] Brunstein, C.G., Noreen, H., DeFor, T.E., Maurer, D., Miller, J.S., Wagner, J.E., Anti-HLA antibodies in double umbilical cord blood transplantation. Biol. Blood Marrow Transplant. 17:11 (2011), 1704–1708 Epub 2011/05/24.
97. [97] Takanashi, M., Atsuta, Y., Fujiwara, K., Kodo, H., Kai, S., Sato, H., et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 116:15 (2010), 2839–2846 Epub 2010/07/16.
98. [98] Gutman, J.A., McKinney, S.K., Pereira, S., Warnock, S.L., Smith, A.G., Woolfrey, A.E., et al. Prospective monitoring for alloimmunization in cord blood transplantation: “virtual crossmatch” can be used to demonstrate donor-directed antibodies. Transplantation 87:3 (2009), 415–418 Epub 2009/02/10.
99. [99] Ruggeri, A., Rocha, V., Masson, E., Labopin, M., Cunha, R., Absi, L., et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Societe Francophone d'Histocompatibilite et d'Immunogenetique (SFHI) and Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) analysis. Haematologica 98:7 (2013), 1154–1160 Epub 2012/12/18.
100. [100] Spellman, S., Bray, R., Rosen-Bronson, S., Haagenson, M., Klein, J., Flesch, S., et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 115:13 (2010), 2704–2708 Epub 2010/01/22.
101. [101] Ciurea, S.O., Thall, P.F., Wang, X., Wang, S.A., Hu, Y., Cano, P., et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118:22 (2011), 5957–5964 Epub 2011/10/05.
102. [102] Ciurea, S.O., Thall, P.F., Milton, D.R., Barnes, T.H., Kongtim, P., Carmazzi, Y., et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 21:8 (2015), 1392–1398 Epub 2015/05/20.